Valuing Patents and Technology: Income Approach Methods for Intellectual Property

The Hong Kong Monetary Authority’s (HKMA) December 2024 circular on the recognition of intangible assets as collateral under the Banking (Capital) Rules (Cap. 155) has placed a sharp focus on the valuation methodologies for intellectual property (IP). Concurrently, the Hong Kong Stock Exchange (HKEX) has intensified its scrutiny of technology-driven listings under Listing Rules Chapter 18C, specifically requiring sponsors to justify the fair value of patents and proprietary technology disclosed in prospectuses. These twin regulatory pressures have exposed a critical gap: while real estate and financial instruments have mature valuation frameworks, patents and technology assets remain notoriously opaque. For CFOs of Hong Kong-listed or listing-aspirant technology firms, and for the financial advisors structuring their capital, the income approach — specifically the relief-from-royalty and multi-period excess earnings methods — has emerged as the only defensible path to satisfying both the SFC’s Code of Conduct for sponsors and the HKMA’s new collateral assessment guidelines. This article dissects the mechanics of these methods, the specific data inputs required, and the common pitfalls that trigger regulatory pushback, drawing on the 2023 HKEX consultation conclusions on Chapter 18C and the latest International Valuation Standards (IVS) 210.

The Regulatory Imperative for Income-Based IP Valuation

The shift toward income-based methods is not a theoretical preference but a direct response to enforcement actions. In 2024, the SFC reprimanded three sponsors for inadequate due diligence on IP valuations in Chapter 18C applications, citing a failure to verify revenue projections linked to patented technology. The HKEX Listing Decision LD143-2023 further clarified that the market approach — comparing patents to allegedly similar transactions — is insufficient without demonstrable evidence of comparable license agreements. This has forced practitioners to adopt the income approach, which the International Valuation Standards Council (IVSC) has codified in IVS 210 as the primary method for technology assets with identifiable cash flows.

The SFC’s Code of Conduct and Sponsor Liability

Paragraph 17 of the SFC’s Code of Conduct for Sponsors requires that any valuation included in a listing document be “reasonable and supportable by objective evidence.” For patents, this means the sponsor must demonstrate that the projected cash flows attributable to the IP are distinct from the company’s general business goodwill. The HKEX’s 2023 consultation on Chapter 18C explicitly warned against “bundling” technology valuations with overall enterprise value, a practice that led to the rejection of three Special Purpose Acquisition Company (SPAC) de-SPAC targets in 2024. The income approach, by isolating patent-specific revenue streams, directly addresses this regulatory demand.

The HKMA’s Collateral Recognition Framework

The HKMA’s December 2024 circular (Ref: B1/15C) permits banks to accept patents as eligible collateral for regulatory capital purposes, but only if the valuation is conducted using a method that “generates a reliable estimate of future economic benefits.” The circular explicitly cites the multi-period excess earnings method (MPEEM) as the preferred approach, rejecting cost-based methods as “backward-looking and insufficient for collateral assessment.” For Hong Kong-listed companies seeking to monetize their IP through secured lending, this makes the income approach not just a compliance exercise but a liquidity necessity.

The Relief-from-Royalty Method: Mechanics and Application

The relief-from-royalty method (RRM) estimates patent value by calculating the present value of the royalty payments the owner would have to pay a third party to license the same technology. This is the most commonly used income approach for patents with established market comparables, but its application in the Hong Kong context requires careful calibration of the royalty rate.

Selecting the Royalty Rate: The Comparable License Challenge

The central input in RRM is the royalty rate, expressed as a percentage of net revenue attributable to the patented product. The SFC’s 2023 thematic review of sponsor valuations found that 68% of Chapter 18C applications used royalty rates derived from publicly available license agreements, but only 12% of those applications provided evidence that the comparables were economically similar. The acceptable approach, per IVS 210 paragraph 50, is to use the “25% rule” only as a starting point, then adjust for:

• Industry-specific profit margins (e.g., biotechnology patents in Hong Kong-listed firms average 12-18% royalty rates, while software patents average 5-8%, per the 2024 Hong Kong Venture Capital Association survey).
• The patent’s remaining legal life under the Patents Ordinance (Cap. 514), which grants 20 years from filing date.
• Geographic scope: patents registered under the PRC Patent Law, which covers Hong Kong under the Basic Law, have different enforcement costs than those registered directly in Hong Kong.

Forecasting the Revenue Base

The revenue base must be limited to products that directly embody the patent. The HKEX Listing Decision LD143-2023 rejected a valuation where the sponsor included revenue from a software platform that used the patented algorithm only as a minor component. The correct approach, as applied in the 2024 listing of a Shenzhen-based semiconductor firm on the Main Board, was to isolate revenue from the specific chip design covered by the patent, which constituted 34.2% of total group revenue. The forecast period should not exceed the patent’s remaining life — a common error where valuers project 10 years of revenue for a patent with only 6 years left under Cap. 514.

Discount Rate and Tax Shield

The discount rate for RRM should reflect the risk of the patent-specific cash flows, not the company’s weighted average cost of capital (WACC). The SFC’s 2024 guidance on technology valuations recommends a build-up method starting with the Hong Kong risk-free rate (the 10-year Exchange Fund Notes yield, which stood at 3.84% as of 31 December 2024) plus an equity risk premium of 5.5-7.0% for technology firms, plus a patent-specific risk premium of 2-4% for obsolescence risk. The tax shield — the royalty expense that would be deductible if the patent were licensed — must be calculated at the Hong Kong profits tax rate of 16.5%, unless the patent is held through a BVI or Cayman entity, in which case the applicable rate is zero under the territorial tax system.

The Multi-Period Excess Earnings Method for Complex Technology Stacks

The MPEEM is required when a patent is part of a broader technology platform that includes trade secrets, software code, and customer relationships. This method isolates the patent’s contribution by deducting the returns attributable to other intangible assets from the total cash flow of the product or business unit.

Identifying Contributory Assets and Their Returns

Under MPEEM, the valuer must first identify all contributory intangible assets (CIAs) that support the patent’s revenue generation. For a Hong Kong-listed fintech company, these typically include:

• Software code: valued using the cost approach at the replacement cost of development, per IVS 210.
• Customer relationships: valued using the multi-period excess earnings method themselves, creating a recursive valuation problem that requires simultaneous equation solving.
• Trade name: valued using the relief-from-royalty method at a rate of 1-3% of revenue, consistent with HKEX practice for financial services brands.

The return on each CIA is calculated as the fair value of the CIA multiplied by a required rate of return specific to that asset class. The SFC’s 2024 guidance on fintech valuations specifies that the required return on software code should be 14-18%, while customer relationships should carry a 20-25% return due to higher attrition risk in Hong Kong’s competitive market.

The Residual Cash Flow Calculation

The patent’s value is the present value of the residual cash flow after deducting the returns on all CIAs. The formula is:

Patent Cash Flow = Total Product Cash Flow — (Return on Working Capital + Return on Fixed Assets + Return on Software + Return on Customer Relationships + Return on Trade Name)

A common error in Hong Kong Chapter 18C applications is including a return on goodwill, which the HKEX explicitly prohibits in its 2023 consultation conclusions. Goodwill is a residual itself and cannot be a contributory asset. The 2024 listing of a biotech firm on the Main Board was delayed by three months because the sponsor’s valuer included a 2% return on assembled workforce, which the SFC rejected as not meeting the “identifiable” test under HKAS 38.

Tax Amortisation Benefit

Under Hong Kong tax law, patents acquired in a business combination are amortised for tax purposes over their remaining legal life, not exceeding 20 years. The MPEEM must include a tax amortisation benefit (TAB) adjustment, which increases the patent’s value by the present value of the tax savings from amortisation. The TAB factor is calculated as:

TAB = 1 / [1 — (Tax Rate × Annuity Factor for Tax Life)]

For a patent with 10 years remaining life and a 16.5% tax rate, the TAB factor is approximately 1.12, meaning the pre-TAB patent value must be increased by 12% to reflect the tax shield. This adjustment is mandatory under the HKMA’s December 2024 circular for collateral valuation, but many Hong Kong valuations still omit it, leading to undervaluation by 10-15%.

Data Requirements and Common Pitfalls in Hong Kong Filings

The income approach is only as reliable as the data inputs. Both the SFC and HKEX have published specific data requirements that sponsors and valuers must meet. Failure to comply results in comment letters, valuation rejections, and, in the case of the 2024 reprimand, sponsor fines of HKD 10 million.

Revenue Attribution and Segment Reporting

HKEX Listing Rule 14.36 requires that any patent valuation disclosed in a circular or prospectus be supported by audited segment revenue data. The valuer must demonstrate that the revenue attributed to the patent is derived from the company’s management accounts and reconciled to the audited financial statements under HKFRS 8. A 2024 enforcement case involved a Hong Kong-listed electronics manufacturer that attributed 40% of its revenue to a patent, but the auditor’s report showed that the patent-related product line contributed only 12% of group revenue. The SFC required a restatement and a revised valuation.

Discount Rate Documentation

The SFC’s 2024 thematic review found that 45% of Chapter 18C applications used a single discount rate for all patent cash flows, ignoring the time-varying risk profile of technology assets. The correct approach is to use a term structure of discount rates, with higher rates for later years to reflect increasing obsolescence risk. The HKEX’s 2023 consultation conclusions recommend a 50-100 bps per year increase in the discount rate for patents in the semiconductor and biotechnology sectors. For example, a patent with a 5-year forecast period should have a discount rate of 12% in Year 1, 13% in Year 2, and so on, rather than a flat 12%.

Legal and Regulatory Risk Adjustments

Patents registered under the PRC Patent Law but enforced in Hong Kong carry specific legal risks that must be reflected in the cash flow projections. The 2024 amendments to the PRC Patent Law introduced punitive damages for willful infringement, which increases the enforceability of patents but also introduces litigation cost risks. Valuations must include a probability-weighted adjustment for litigation costs, typically 2-5% of projected revenue, based on the average litigation rate for Hong Kong-listed technology firms (7.3% per the 2024 Hong Kong Intellectual Property Department annual report). Failure to include this adjustment was cited in the SFC’s reprimand of a sponsor in March 2024.

Actionable Takeaways for CFOs and Financial Advisors

1. For any patent valuation disclosed in a Chapter 18C listing document or HKMA collateral submission, mandate the use of the relief-from-royalty or MPEEM method, and require the valuer to provide a detailed reconciliation of the royalty rate to comparable license agreements registered with the Hong Kong Intellectual Property Department.
2. Ensure that the revenue base for the income approach is limited to audited segment data under HKFRS 8, with explicit confirmation from the auditor that the patent-related revenue is separately identifiable in the management accounts.
3. Apply a term structure of discount rates that increases by 50-100 bps per year for technology patents, and document the build-up method using the Hong Kong risk-free rate as of the valuation date.
4. Include the tax amortisation benefit adjustment in all MPEEM valuations, calculated at the Hong Kong profits tax rate of 16.5%, and confirm that the patent’s remaining legal life under the Patents Ordinance (Cap. 514) is the amortisation period.
5. For cross-border patent portfolios held through BVI or Cayman entities, adjust the tax shield to zero and document the territorial tax treatment explicitly in the valuation report to satisfy both the SFC’s Code of Conduct and the HKMA’s circular on intangible collateral.